Prodrugs in cardiovascular therapy.

Molecules

Department of Biomedical Engineering, McGill University, 3775 University Street, Montreal, QC, Canada H3A2B4.

Published: May 2008

Prodrugs are biologically inactive derivatives of an active drug intended to solve certain problems of the parent drug such as toxicity, instability, minimal solubility and non-targeting capabilities. The majority of drugs for cardiovascular diseases undergo first-pass metabolism, resulting in drug inactivation and generation of toxic metabolites, which makes them appealing targets for prodrug design. Since prodrugs undergo a chemical reaction to form the parent drug once inside the body, this makes them very effective in controlling the release of a variety of compounds to the targeted site. This review will provide the reader with an insight on the latest developments of prodrugs that are available for treating a variety of cardiovascular diseases. In addition, we will focus on several drug delivery methodologies that have merged with the prodrug approach to provide enhanced target specificity and controlled drug release with minimal side effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245309PMC
http://dx.doi.org/10.3390/molecules13051156DOI Listing

Publication Analysis

Top Keywords

parent drug
8
cardiovascular diseases
8
drug
6
prodrugs
4
prodrugs cardiovascular
4
cardiovascular therapy
4
therapy prodrugs
4
prodrugs biologically
4
biologically inactive
4
inactive derivatives
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!